⚠️ Auto-extracted class page seeded 2026-05-21 on the user’s prompt that the Kane 2025 super-adjuvant NP modality is more generally relevant to cancer interventions. Anchored on Kane 2025 (full PDF verified — see kane-2025-super-adjuvant-nanoparticles) plus prior-art references that are NOT yet seeded as full study pages — quantitative claims for those references are taken from their abstracts and from how Kane 2025 cites them. Verify before relying on those specific numbers.

Nanoparticle Immunoadjuvants (NP-formulated dual-PRR cancer-vaccine adjuvants)

A class of lipid- or polymer-based nanoparticles co-encapsulating two or more physically distinct innate-immune agonists (most commonly a STING agonist paired with a TLR4 agonist — but also TLR3, TLR7/8, TLR9 combinations) on a single ~30–60 nm PEGylated particle, with modular antigenic payload (peptides, whole tumor lysate, mRNA, neoantigens) co-delivered to the same particle or co-administered. Designed to overcome the historically limited efficacy of single-adjuvant subunit vaccines and the safety burden of whole-pathogen vaccines by harnessing PAMP synergy through coordinated activation of shared downstream IRF3/IRF5/IRF7 transcription factors ¹².

This class is preclinical-only as of 2026 — no NP-formulated dual-PRR cancer-vaccine has entered Phase 1. But the prior-art and current-art accumulating since ~2019 (Atukorale + Mirkin + Irvine + Ruscetti groups, among others) constitute a distinct intervention modality that the wiki tracks as cancer biology shifts from systemic mono-agonist STING-agonist small-molecule trials (largely disappointing in efficacy) to lymph-node-targeted multi-PAMP NP-formulated platforms.

Why aged hosts matter for this class

Cancer is overwhelmingly an aging disease. ~60% of cancers and ~70% of cancer mortality occur in people ≥65 in developed nations (see cancer § “The aging-cancer paradox”). The population that needs effective cancer vaccines most is the same population that responds worst to conventional adjuvants: immunosenescent older adults exhibit declining naïve T cell pools, impaired DC migration, reduced TLR4 responsiveness in PBMCs, and chronic low-grade inflammaging that desensitizes acute innate-immune signaling (see immunosenescence and chronic-inflammation).

Super-adjuvant platforms in principle compensate for immunosenescent baseline by maximizing per-particle innate-immune activation: more IFN-α/β per DC, more antigen-processing-machinery upregulation, better lymph-node delivery. But none of the published preclinical data tests this in aged hosts. All efficacy is in young immunocompetent mice (8–12-week-old C57BL/6 or BALB/c). Translation to immunosenescent older cancer patients is the central open question.

needs-human-replication · needs-aged-host-validation

Mechanism

The core mechanism is PAMP-synergy through coordinated IRF activation:

Agonist class	Receptor	Adapter	Kinase	Transcription factor
Cyclic dinucleotides (cdGMP, 2′3′-cGAMP, diABZI)	[[sting	STING]]	(TBK1/IKKε direct)	TBK1, IKKε
MPLA / LPS	[[tlr4	TLR4]] (TRIF arm)	TRIF + TRAM	TBK1, IKKε
MPLA / LPS	[[tlr4	TLR4]] (MyD88 arm)	MyD88 + TIRAP	IRAK4, IRAK1
Poly(I:C)	TLR3	TRIF	TBK1	IRF3, NF-κB
R848 / resiquimod	TLR7/8	MyD88	IRAK	IRF7, NF-κB
CpG ODN	TLR9	MyD88	IRAK	IRF7, NF-κB

When two agonists from this table are presented to the same APC on the same nanoparticle (not as free agonists), the kinetics of receptor engagement and downstream IRF/NF-κB activation produce >4-fold IFN-α/β amplification vs single agonists ¹². The synergy is shared-IRF dependent: IRF3, IRF5, and IRF7 KO iBMDMs all show blunted IFN-I production with dual-adjuvant NPs vs WT, and IFNAR-blockade in vivo abolishes tumor protection ¹. The synergy is NP-dependent: free-agonist combinations do NOT reliably reproduce the in-vivo efficacy of NP-formulated combinations, likely because NP encapsulation controls receptor-encounter kinetics and bypasses serum degradation of cyclic dinucleotides.

Secondary mechanisms:

Lymph-node-directed drainage. ~30–60 nm PEGylated NPs preferentially drain to nearest draining lymph nodes after s.c. injection (the size window for direct lymphatic uptake is ~10–100 nm; smaller NPs leak into blood, larger NPs are trapped at the injection site). Empty and dual-adjuvant NPs drain similarly at 1 h but dual-adjuvant NPs accumulate >3-fold more after boost (24 h post-boost), consistent with active DC-mediated ferrying after dual-PRR activation ¹.
Antigen-processing machinery upregulation. Dual-adjuvant NPs synergistically upregulate Tap1, Tap2, Erap1, B2m, H2-K1, H2-D1 in primary CD11c⁺ DCs — the peptide-MHC-I loading machinery — providing a mechanistic basis for the enhanced CD8⁺ T cell priming observed downstream ¹.
SASP-mediated TME remodeling (when combined with senescence-inducing therapy). In immune-cold solid tumors (notably PDAC), pre-treatment with senescence-inducing RAS-targeted therapy (trametinib MEK inhibitor + palbociclib CDK4/6 inhibitor) generates a therapy-induced senescent (TIS) tumor population whose SASP remodels the immunosuppressive TME — restoring immune infiltration that NP-delivered dual-PRR agonists can then exploit ³. This is the cancer-aging interface most directly relevant to this wiki: the same biology this wiki tracks as pathological in aged tissues (chronic SASP-driven inflammaging, immunosenescent stromal dysfunction) is being deliberately and acutely deployed as a vaccine-priming strategy in tumors. The therapeutic window between productive acute SASP and pathological chronic SASP is the central translational question.

Representative platforms

Kane 2025 — STING + TLR4 dual-PRR lipid NP for platform cancer vaccination

The most recent and fully-characterized entry in the class.

Composition. Lipid NP co-encapsulating cdGMP (STING agonist, hydrophilic) + MPLA (TLR4 agonist, hydrophobic) at 2.5:1 cdGMP/MPLA mole ratio, ~30–60 nm PEGylated, total NP lipid 10 mg/mL. Antigens co-administered (peptides or whole tumor lysate).
In vivo efficacy. Multivalent B16F10 peptide (Trp1+Trp2+gp100) prime/boost vaccination: 100% (10/10) tumor-free at day 48; 80% (8/10) systemic rechallenge rejected. Whole-lysate vaccination: 69% (9/13) B16F10 melanoma, 88% (7/8) Panc02 PDAC, 75% (6/8) 4T1 TNBC rejection — 100% systemic-rechallenge rejection across all three models.
IFNAR blockade abolishes efficacy → clean demonstration that type I IFN through IFNAR is the necessary effector.
See kane-2025-super-adjuvant-nanoparticles for the full extracted study record. ¹

Chibaya 2024 — STING + TLR4 NP combined with senescence-inducing TIS for PDAC (the cancer-aging bridge)

The same Atukorale + Fitzgerald + Ruscetti group’s earlier paper directly relevant to this wiki because it explicitly leverages therapy-induced senescence to remodel the immune-cold pancreatic-ductal-adenocarcinoma microenvironment.

Combination. Lipid NP STING (cdGMP) + TLR4 (MPLA) dual agonist + systemic trametinib (MEK inhibitor) + palbociclib (CDK4/6 inhibitor) — the “T/P” regimen induces senescence-like arrest in RAS-mutant tumor cells, with the resulting SASP remodeling the immunosuppressive TME.
Mouse models. Transplanted + autochthonous (genetically engineered) PDAC models. Both tumor STING AND host STING were required for the response (cell-autonomous tumor sensing + host innate sensing both load-bearing).
Human PDAC samples. STING/TLR4-mediated IFN-I signaling correlated with enhanced NK and CD8⁺ T cell infiltration ex vivo.
The conceptual bridge for the aging wiki: TIS is being deployed as a vaccine-priming strategy — the same SASP biology that drives chronic inflammaging in aged tissues is harnessed acutely to break tumor immune cold. Cancer-aging trade-off in microcosm.
Patent application (PCT/US2024/029125) filed by UMass Chan + UMass Amherst on combinations of NP-loaded immune agonists with RAS-targeted therapies; commercial development through NanoVax Therapeutics. ³

Baljon 2024 — STING + TLR4 with peptide neoantigens (independent group, optimized combinations)

Independent group reporting an optimized lipid NP for STING + TLR4 agonist co-delivery with peptide neoantigens. Shows the class is not exclusive to the Atukorale group and that the optimal combinations are an active design space. ⁴

Nakamura 2021 — STING-LNP overcomes anti-PD-1 resistance via NK activation

Mono-agonist (STING only) lipid nanoparticle — but mechanistically important: shows STING-LNP overcomes anti-PD-1 resistance in B16F10 melanoma lung metastasis via NK cell activation. Suggests NP-STING combinations with checkpoint blockade are the natural Phase 1 combination strategy for the dual-PRR platforms above. ⁵

Atukorale 2019 — original dual-PRR NP precedent (systemic codelivery; CDN + MPLA)

The Atukorale group’s original 2019 paper demonstrating that NP encapsulation of synergistic immune agonists enables systemic codelivery to tumor sites with IFN-β-driven antitumor immunity. The conceptual precedent for Kane 2025 + Chibaya 2024. ⁶

Pradhan 2021 — biophysics of MPLA + CpG NP synergy (mechanistic deep-dive)

Mechanistic deep-dive on TRAF6-IRF5 kinetics, TRIF, and biophysical factors driving particle-mediated MPLA + CpG synergy. Establishes that NP-mediated co-presentation (not just co-administration of free agonists) is responsible for the synergy. ²

Aging-context relevance

The intervention class is mechanistically and translationally interesting to the aging wiki for several reasons:

Cancer is an aging disease. Every cancer-vaccine intervention is implicitly an aging-relevant intervention. The patients who need them most are immunosenescent.
Immunosenescent compensation. Super-adjuvants in principle compensate for impaired baseline APC function in aged hosts, but this is untested in aged-mouse or older-adult-human cohorts. Validating dual-PRR NP super-adjuvants in 18–22-month C57BL/6 mice is the most aging-relevant follow-up.
TIS-as-vaccine-priming exploits SASP biology. Chibaya 2024 deliberately induces senescence (via trametinib + palbociclib) to remodel the immune-cold PDAC TME. The same SASP biology that drives chronic inflammaging in aged tissues is being weaponized acutely against tumors. Therapeutic window is the key translational question.
STING modulator class divergence. cgas-sting STING antagonists (H-151 etc.) are being explored to suppress aging-related chronic IFN-I (inflammaging); STING agonists (this class) for acute cancer-vaccine priming. The same pathway is both a target of inhibition (chronic) and amplification (acute) depending on the aging-context — the wiki’s recurring dual-edged-sword framing of IFN-I biology applies here.
mRNA-LNP infrastructure carryover. The lipid-NP infrastructure that COVID mRNA vaccines mainstreamed (Acuitas, Genevant, Moderna lipid libraries) is directly applicable to NP-cancer-adjuvant platforms. The translational ramp is potentially faster than first-in-class pharmacological interventions because the lipid-NP regulatory + GMP-manufacturing pathways are established.

Limitations and gaps

No human trials of dual-PRR NP cancer adjuvants as of 2026. Mono-agonist STING-LNP trials (e.g., MK-2118, ulevostinag) have been ongoing but largely disappointing in efficacy. NanoVax Therapeutics (Kane + Atukorale-founded) holds patent (US Patent 12377118, 8/5/2025) but no announced NCT.
Aged-host efficacy untested. All published efficacy in young C57BL/6 or BALB/c mice (typically 8–12 weeks). needs-aged-host-validation
Cytokine-release-syndrome risk unmodeled. Systemic IFN-I storm is the dose-limiting concern; no large-animal toxicology or comprehensive cytokine-release screens reported. Histopathology of major organs not assessed in Kane 2025 (acknowledged by authors). long-term-unknown
TLR4 hyporesponsiveness in aged human PBMCs. Older adults exhibit declining TLR4 surface expression and signaling capacity in monocytes. Whether the supraphysiological PRR amplification this NP class provides overcomes that baseline hyporesponsiveness is unmodeled. needs-mechanism
Therapeutic window for TIS-as-priming (Chibaya 2024 axis). Distinguishing productive acute SASP (cancer-vaccine priming) from pathological chronic SASP (inflammaging, secondary malignancy) is the central translational question — particularly relevant for older patients with baseline senescent-cell burden. dose-response-unclear
Customizability across non-CDN STING agonists not tested. Kane 2025 uses cdGMP (cyclic dinucleotide). Synthetic non-CDN agonists (diABZI, MSA-2) have superior PK and serum stability but compatibility with the dual-NP platform is untested. needs-replication
Combination with checkpoint blockade not tested in Kane 2025. Nakamura 2021 showed STING-LNP overcomes anti-PD-1 resistance; whether the dual-PRR NP super-adjuvant + PD-1/PD-L1 blockade combination further amplifies efficacy is the natural Phase 1 combination strategy. needs-replication

Cross-references

cgas-sting § STING agonists for cancer immunotherapy — pathway-level home for STING-agonist biology
type-i-interferon-signaling § STING + TLR4 dual-PAMP nanoparticle adjuvants — pathway-level home for IFN-I amplification axis
cancer § Modern therapeutic landscape — cancer-phenotype-level home for NP-adjuvant modality
immunosenescence — the aged-host condition that motivates super-adjuvant development
chronic-inflammation — the SASP biology weaponized in Chibaya 2024
cellular-senescence — therapy-induced senescence as vaccine-priming strategy (Chibaya 2024)
bacterial-cancer-therapy — adjacent modality (live-bacterium cancer therapy); same conceptual lineage of innate-immune amplification at the tumor site
kane-2025-super-adjuvant-nanoparticles — anchor study for the class

Footnotes

kane-2025-super-adjuvant-nanoparticles · doi:10.1016/j.xcrm.2025.102415 · PMID:41072409 · PMC:PMC12629812 · in-vitro+in-vivo · “Super-adjuvant nanoparticles for platform cancer vaccination” · Kane GI et al. · Cell Reports Medicine 6(10):102415 · 2025 · n=3–4 biological replicates in vitro; 5–13 mice per group in vivo · model: mouse macrophages + iBMDMs (Irf3/Irf5/Irf7 KO) + primary mouse splenic CD11c⁺ DCs + primary human DCs (3 donors); in vivo C57BL/6 (B16F10, Panc02) + BALB/c (4T1) · archive: downloaded (gold OA via PMC) · full-PDF verified ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶
doi:10.1126/sciadv.abd4235 · “TRAF6-IRF5 kinetics, TRIF, and biophysical factors drive synergistic innate responses to particle-mediated MPLA-CpG co-presentation” · Pradhan P, Toy R, Jhita N, Atalis A, Pandey B, Beach A, Blanchard EL, Moore SG, Gaul DA, Santangelo PJ et al. · Sci Adv 7:eabd4235 · 2021 · model: mouse macrophages + DCs; biochemical reconstitution · archive: pending download (gold OA) · the canonical mechanistic paper for why particle-mediated PAMP co-presentation produces synergy that free-agonist co-administration does not. **Full study page not yet seeded; claims here are from title + Kane 2025’s citation summary — verify before relying. needs-full-extraction ↩ ↩² ↩³
doi:10.1126/scitranslmed.adj9366 · PMID:39196961 (NCBI lookup recommended) · in-vitro+in-vivo · “Nanoparticle delivery of innate immune agonists combined with senescence-inducing agents promotes T cell control of pancreatic cancer” · Chibaya L*, DeMarco KD*, Lusi CF, Kane GI, Brassil ML, Parikh CN, Murphy KC, Chowdury SR, Li J, Ma B, Naylor TE, Cerrutti J, Mori H, Diaz-Infante M, Peura J, Pitarresi JR, Zhu LJ, Fitzgerald KA, Atukorale PU#, Ruscetti M# · Sci Transl Med 16(762):eadj9366 · 28 Aug 2024 · model: transplanted + autochthonous PDAC (KPC-derived + GEMM); human PDAC samples · archive: downloaded (bronze OA via HHS Public Access PMC) · STING+TLR4 dual-agonist lipid NP + MEK inhibitor (trametinib) + CDK4/6 inhibitor (palbociclib) “T/P”; senescence-induced SASP remodels immune-cold PDAC TME → NP-delivered dual-PRR agonists prime IFN-I-driven T cell response; both tumor and host STING required; durable anti-tumor efficacy. **Full study page not yet seeded — claims here are from the abstract + the editor’s summary on the PMC preprint version; verify quantitative claims before relying. needs-full-extraction ↩ ↩²
doi:10.1021/acsnano.3c04471 · “A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists” · Baljon JJ, Kwiatkowski AJ, Pagendarm HM, Stone PT, Kumar A, Bharti V, Schulman JA, Becker EW, Roth EW, Christov P, Bonami RH · ACS Nano 18(8):6845–6862 · 2024 · model: mouse (B16F10 + MC38 + 4T1) · archive: downloaded (hybrid OA) · **Full study page not yet seeded; claims here are from title + abstract — verify before relying. needs-full-extraction ↩
doi:10.1136/jitc-2021-002852 · “STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation” · Nakamura T, Sato T, Endo R, Sasaki S, Takahashi N, Sato Y, Hyodo M, Hayakawa Y, Harashima H · J Immunother Cancer 9:e002852 · 2021 · model: mouse B16F10 lung metastasis · archive: pending download (gold OA) · **Full study page not yet seeded; claims here are from title + abstract — verify before relying. needs-full-extraction ↩
doi:10.1158/0008-5472.CAN-19-0381 · “Nanoparticle Encapsulation of Synergistic Immune Agonists Enables Systemic Codelivery to Tumor Sites and IFNβ-Driven Antitumor Immunity” · Atukorale PU, Raghunathan SP, Raguveer V, Moon TJ, Zheng C, Bielecki PA, Wiese ML, Goldberg AL, Covarrubias G, Hoimes CJ, Karathanasis E · Cancer Research 79(20):5394–5406 · 2019 · model: mouse (multiple tumor models) · archive: closed (not_oa) · **Full study page not yet seeded; claims here are from title + abstract — verify before relying. no-fulltext-access needs-full-extraction ↩

🧬 Aging Wiki

Explorer

nanoparticle-immunoadjuvants